Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 17;21(12):4325.
doi: 10.3390/ijms21124325.

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Iris Z Uras  1 , Herwig P Moll  2 , Emilio Casanova  2   3
Affiliations
Review

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Iris Z Uras et al. Int J Mol Sci. .

Abstract

Lung cancer is the most frequent cancer with an aggressive clinical course and high mortality rates. Most cases are diagnosed at advanced stages when treatment options are limited and the efficacy of chemotherapy is poor. The disease has a complex and heterogeneous background with non-small-cell lung cancer (NSCLC) accounting for 85% of patients and lung adenocarcinoma being the most common histological subtype. Almost 30% of adenocarcinomas of the lung are driven by an activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. The ability to inhibit the oncogenic KRAS has been the holy grail of cancer research and the search for inhibitors is immensely ongoing as KRAS-mutated tumors are among the most aggressive and refractory to treatment. Therapeutic strategies tailored for KRAS+ NSCLC rely on the blockage of KRAS functional output, cellular dependencies, metabolic features, KRAS membrane associations, direct targeting of KRAS and immunotherapy. In this review, we provide an update on the most recent advances in anti-KRAS therapy for lung tumors with mechanistic insights into biological diversity and potential clinical implications.

Keywords: EGFR; KRAS; NSCLC; STK11; degraders; immunotherapy; lung adenocarcinoma; metabolic rewiring; p53; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The two states of RAS family GTPases. GTP- and GDP-bound states are directed by GEFs and GAPs. GEFs stimulate the exchange of GDP to GTP, promoting activation of RAS (On). GAPs drive GTP hydrolysis and return to inactive GDP-bound status (Off). The thickness of the arrows indicates the strength of GTP binding as well as the (hyper)activation of downstream effectors. The red cross indicates the impairment of GTP hydrolysis. GEF: guanine nucleotide exchange factor; GAP: GTPase-activating protein; GTP: guanosine triphosphate; GDP: guanosine diphosphate; RAS: rat sarcoma proto-oncogene
Figure 2
Figure 2
KRAS signaling in non-small-cell lung cancer (NSCLC). Schematic presentation of signaling pathways initiated by oncogenic KRAS aberrations is illustrated in a simplified fashion. RAF: rat fibrosarcoma; MEK: mitogen-activated protein kinase kinase; ERK: extracellular regulated kinase; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; mTOR: mechanistic target of rapamycin kinase; RALGDS: Ral guanine nucleotide dissociation stimulator; KRAS: Kirsten rat sarcoma viral oncogene homolog; CDK4/6: cyclin-dependent kinase 4/6; RHOA: Ras homolog family member; FAK: focal adhesion kinase; IKK: IkappaB kinase; IκB: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor; NF-κB: nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells; Bad: BCL2-associated agonist of cell death; BCL-XL: B-cell lymphoma-extra large; RAL: Ras-like protein; PLD1: phospholipase D1; TBK1: TANK binding kinase 1; TIAM1: T lymphoma invasion and metastasis-inducing protein 1; RAC: Ras-related C3 botulinum toxin substrate 1; JNK: c-Jun N-terminal kinase.
Figure 3
Figure 3
Therapeutic approaches to tackle KRAS mutant NSCLC in patients. Selected compounds and their targets are listed. CDK4/6: cyclin-dependent kinase 4/6; Chk1: checkpoint kinase 1; CRBN: cereblon; PROTAC: proteolysis-targeting chimeras; VHL: von Hippel–Lindau disease tumor suppressor; HSP90: heat shock protein 90; RAF: rat fibrosarcoma; MEK: mitogen-activated protein kinase kinase; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; mTOR: mechanistic target of rapamycin kinase; KRAS: Kirsten rat sarcoma viral oncogene homolog; FAK: focal adhesion kinase; ERBB: human epidermal growth factor receptor; PD-1: programmed cell death protein 1; PD-L: programmed cell death 1 ligand; MAPK: mitogen-activated protein kinase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA. Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Socinski M.A., Evans T., Gettinger S., Hensing T.A., Van Dam Sequist L., Ireland B., Stinchcombe T.E. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143:e341S. doi: 10.1378/chest.12-2361. - DOI - PMC - PubMed
    1. Polo V., Besse B. Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann. Oncol. 2013;25:1283–1293. doi: 10.1093/annonc/mdt529. - DOI - PubMed
    1. Hildebrandt M.A.T., Gu J., Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin. Drug Metab. Toxicol. 2009;5:745–755. doi: 10.1517/17425250902973711. - DOI - PMC - PubMed
    1. Ahmadzada T., Kao S., Reid G., Noyer M., Mahar A., Cooper W.A. An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. J. Clin. Med. 2018;7:153. doi: 10.3390/jcm7060153. - DOI - PMC - PubMed

MeSH terms